Bausch Health Companies Inc

Latest Bausch Health Companies Inc News and Updates

  • Bausch + Lomb
    IPOs

    Eye Care Company Bausch + Lomb Seeks Major IPO in May

    Global eye care company Bausch + Lomb is going public this week with likely the second-largest IPO in 2022. Here's what investors can expect.
    By Kathryn Underwood
  • uploads///teva loss
    Company & Industry Overviews

    Teva Pharmaceutical: Earnings Trends and Recent Developments

    Teva Pharmaceutical’s net income and diluted EPS in the first nine months of 2018 amounted to $541.0 million and $0.53, respectively.

    By Daniel Collins
  • uploads///Bausch
    Company & Industry Overviews

    A Financial Overview of Bausch Health in October

    Bausch Health’s (BHC) net revenues declined from $4.3 billion in H1 2017 to $4.1 billion in H1 2018, reflecting an ~5.0% year-over-year decline.

    By Daniel Collins
  • uploads///AdobeStock_
    Earnings Report

    Bausch Health Raises Guidance, Shares Follow

    Today, Bausch Health reported its second-quarter earnings results before the market opened. It reported revenue of $2.15 billion in the quarter.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    BHC’s Salix Segment: Xifaxan Drove Its Revenues in Q1

    In the first quarter, Bausch Health Companies (BHC) reported revenues of $445 million for its Salix segment.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Bausch Health Companies Raised Its Earnings Guidance

    Bausch Health Companies (BHC) raised its fiscal 2019 adjusted EBITDA guidance from $3.35 billion–$3.50 billion to $3.40 billion–$3.55 billion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Are Bausch Health’s Key Growth Drivers in 2019?

    In its fourth-quarter earnings conference call, Bausch Health Companies (BHC) has highlighted its Bausch + Lomb/International segment and Salix segment as the key growth drivers for the company in fiscal 2018.

    By Margaret Patrick
  • uploads///Losing Bets
    Consumer

    How Is Ackman Redeeming Himself after Herbalife and Valent?

    Pershing Square had a series of disappointing years, with losses of 20.5%, 13.5%, 4%, and 0.7%, respectively, in 2015, 2016, 2017, and 2018.

    By Anuradha Garg
  • uploads///Graph
    Company & Industry Overviews

    What Are Bausch Health’s Core Growth Drivers for Next Five Years?

    Bausch Health (BHC) has categorized seven of its most promising assets, which involve both recently launched and commercialized products as well as late-stage pipeline products.

    By Margaret Patrick
  • uploads///Teva pharma
    Company & Industry Overviews

    A Financial Overview of Teva Pharmaceutical in December

    In the first nine months of 2018, Teva Pharmaceutical’s net revenue fell 16% YoY (year-over-year) to $14.3 billion from $17.0 billion.

    By Daniel Collins
  • uploads///pill _
    Company & Industry Overviews

    Teva Pharmaceutical Stock Rose More than ~8% on December 26

    On December 26, Teva Pharmaceutical (TEVA) stock closed at $15.82, a rise of ~8.43% from its close of $14.59 on December 24.

    By Daniel Collins
  • uploads///pills _
    Company & Industry Overviews

    Bausch’s Ultra Multifocal Contact Lenses Get FDA Approval

    On December 5, Bausch + Lomb announced that the FDA approved its Ultra multifocal contact lenses for patients with astigmatism.

    By Daniel Collins
  • uploads///AstraZeneca
    Company & Industry Overviews

    Why Has AstraZeneca’s Stock Price Increased in 2018?

    On November 19, AstraZeneca’s (AZN) stock price closed at $40.80, which represents ~5% growth from its closing price of $38.78 on October 31.

    By Daniel Collins
  • uploads///bausch
    Company & Industry Overviews

    How Bausch Health’s Financials Look in November

    Bausch Health (BHC) generated revenues of $2.1 billion in the third quarter of this year compared to $2 billion in the third quarter of 2017.

    By Daniel Collins
  • uploads///part  Salix
    Company & Industry Overviews

    Update on Salix Pharmaceuticals’ Revenues and Developments

    Salix Pharmaceutical’s gross profit increased from $318.0 million in the second quarter of 2017 to $377.0 million in the second quarter, reflecting ~19.0% YoY growth.

    By Daniel Collins
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.